25,493 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Acquired by SG Americas Securities LLC

SG Americas Securities LLC purchased a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 25,493 shares of the company’s stock, valued at approximately $49,000.

Several other hedge funds have also made changes to their positions in the stock. RA Capital Management L.P. raised its stake in Tenaya Therapeutics by 4.5% during the 1st quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock valued at $30,099,000 after acquiring an additional 247,703 shares in the last quarter. Vanguard Group Inc. raised its stake in Tenaya Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock valued at $14,973,000 after acquiring an additional 403,472 shares in the last quarter. Integral Health Asset Management LLC raised its stake in Tenaya Therapeutics by 3.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after acquiring an additional 75,000 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Tenaya Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock valued at $737,000 after acquiring an additional 26,103 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Tenaya Therapeutics by 90.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 168,565 shares of the company’s stock valued at $882,000 after acquiring an additional 80,212 shares in the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Stock Performance

Shares of TNYA stock opened at $1.96 on Wednesday. Tenaya Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $7.01. The stock has a market cap of $154.62 million, a PE ratio of -1.28 and a beta of 2.35. The business’s fifty day moving average is $2.13 and its 200-day moving average is $3.14.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. Equities research analysts predict that Tenaya Therapeutics, Inc. will post -1.52 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on TNYA shares. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tenaya Therapeutics has a consensus rating of “Buy” and an average price target of $15.25.

Insider Buying and Selling

In related news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction on Friday, August 16th. The stock was sold at an average price of $2.89, for a total value of $28,171.72. Following the transaction, the chief executive officer now directly owns 188,331 shares in the company, valued at $544,276.59. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 19,539 shares of company stock worth $56,468 in the last three months. 32.76% of the stock is currently owned by insiders.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.